Canaccord Genuity analyst Mark Massaro maintained a Buy rating on Heska Corp (HSKA) today and set a price target of $95. The company’s shares opened today at $82.43.
Massaro wrote:
“We had previously indicated we did not feel the company’s LT targets were achievable, and today’s update affirms our thinking. We reiterate our BUY rating on HSKA and we lower our PT from $108 to $95.”
According to TipRanks.com, Massaro is a top 100 analyst with an average return of 19.3% and a 63.7% success rate. Massaro covers the Healthcare sector, focusing on stocks such as HTG Molecular Diagnostics, Meridian Bioscience Inc, and Quanterix Corporation.
Heska Corp has an analyst consensus of Moderate Buy, with a price target consensus of $92.33.
See today’s analyst top recommended stocks >>
The company has a one-year high of $114.50 and a one-year low of $71.50. Currently, Heska Corp has an average volume of 92.94K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Heska Corp. engages in the provision of veterinary and animal health diagnostic, and specialty products. It operates through two segments: Core Companion Animal Health and Other Vaccines & Pharmaceuticals.
